IBRX - CG Oncology's Promising Bladder Cancer Treatment: Balancing Hope And Risk In Late-Stage Trials
2024-05-03 15:54:13 ET
Summary
- CG Oncology has entered the public market with late-stage clinical trials for its cancer therapy, cretostimogene grenadenorepvec.
- The company is focused on treating non-muscle-invasive bladder cancer, an area of unmet need due to a shortage of standard treatments.
- CG Oncology has shown promising results in its phase 3 study, with a high complete response rate, but its operational runway may be shorter than estimated.